Have a feature idea you'd love to see implemented?
Let us know!
AVDL Avadel Pharmaceuticals Plc
Price (delayed)
$12.44
Market cap
$1.2B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.14
Enterprise value
$1.21B
Avadel Pharmaceuticals plc is a biopharmaceutical company primarily focused on the development and FDA approval of FT218, an investigational, once-nightly, extended-release formulation of sodium oxybate designed to treat excessive daytime
Highlights
The revenue has soared by 73% from the previous quarter
The gross profit has soared by 71% QoQ
The debt has surged by 70% year-on-year and by 2.5% since the previous quarter
The company's equity has shrunk by 51% YoY and by 10% QoQ
Key stats
What are the main financial stats of AVDL
Market
Valuations
Earnings
Shares outstanding
96.27M
Market cap
$1.2B
Enterprise value
$1.21B
Price to earnings (P/E)
N/A
Price to book (P/B)
17.01
Price to sales (P/S)
12.57
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
12.68
Revenue
$95.15M
EBIT
-$97.01M
EBITDA
-$95.46M
Free cash flow
-$114.15M
Per share
Balance sheet
Liquidity
EPS
-$1.14
Free cash flow per share
-$1.19
Book value per share
$0.73
Revenue per share
$0.99
TBVPS
$1.46
Total assets
$157.52M
Total liabilities
$87.23M
Debt
$37.67M
Equity
$70.29M
Working capital
$81.17M
Debt to equity
0.54
Current ratio
2.82
Quick ratio
2.35
Net debt/EBITDA
-0.09
Margins
Efficiency
Dividend
EBITDA margin
-100.3%
Gross margin
94.6%
Net margin
-111.6%
Operating margin
-103.8%
Return on assets
-61.3%
Return on equity
-122.6%
Return on invested capital
-84.4%
Return on capital employed
-85.9%
Return on sales
-102%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
AVDL stock price
How has the Avadel Pharmaceuticals stock price performed over time
Intraday
-1.82%
1 week
-4.75%
1 month
-12.64%
1 year
N/A
YTD
N/A
QTD
-5.15%
Financial performance
How have Avadel Pharmaceuticals's revenue and profit performed over time
Revenue
$95.15M
Gross profit
$90.03M
Operating income
-$98.79M
Net income
-$106.22M
Gross margin
94.6%
Net margin
-111.6%
The net margin has surged by 99% year-on-year and by 61% since the previous quarter
AVDL's operating margin has soared by 99% YoY and by 58% QoQ
The revenue has soared by 73% from the previous quarter
The gross profit has soared by 71% QoQ
Growth
What is Avadel Pharmaceuticals's growth rate over time
Valuation
What is Avadel Pharmaceuticals stock price valuation
P/E
N/A
P/B
17.01
P/S
12.57
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
12.68
Avadel Pharmaceuticals's EPS has increased by 45% YoY and by 38% QoQ
The company's equity has shrunk by 51% YoY and by 10% QoQ
The stock's price to book (P/B) is 13% more than its last 4 quarters average of 15.4
The revenue has soared by 73% from the previous quarter
The price to sales (P/S) is 73% lower than the last 4 quarters average of 47.7
Efficiency
How efficient is Avadel Pharmaceuticals business performance
Avadel Pharmaceuticals's return on sales has surged by 99% YoY and by 62% QoQ
The ROE has soared by 85% YoY and by 18% from the previous quarter
The ROIC has grown by 34% from the previous quarter and by 25% YoY
AVDL's return on assets is up by 33% year-on-year and by 28% since the previous quarter
Dividends
What is AVDL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for AVDL.
Financial health
How did Avadel Pharmaceuticals financials performed over time
The total assets is 81% more than the total liabilities
AVDL's total liabilities has soared by 51% YoY but it is down by 2.5% QoQ
AVDL's quick ratio is down by 25% year-on-year
The debt is 46% smaller than the equity
The debt has surged by 70% year-on-year and by 2.5% since the previous quarter
The company's equity has shrunk by 51% YoY and by 10% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.